Drug prices
Like political leaders on both sides of the aisle, Kennedy has supported measures to lower drug costs.
“Legislators should cap drug prices so that companies can’t charge Americans substantially more than Europeans pay,” Kennedy wrote in a Wall Street Journal op-ed in September.
Kennedy pointed to Ozempic, Novo Nordisk’s popular diabetes drug, as an example, noting how in Germany the drug costs less than one-tenth of its cost in the U.S., where the list price is around $1,000 per month. It’s a similar criticism as the case made by Senator Bernie Sanders, I-Vt., against Novo and Eli Lilly for charging too high a price for their diabetes and weight loss medicines.
During his first term, Trump issued an executive order that would have required Medicare to pay no more than the lowest prices in other OECD countries for drugs. CMS proposed what became known as “the most favored nation” model in November 2020, after Trump lost the election, but it was rescinded before the end of the year.
While Trump has since backed away from the policy, Kennedy’s past support suggests how the idea may still circulate in a second Trump administration.
Source: https://www.biopharmadive.com/news/rfk-jr-trump-administration-pharma-fda-policies-views/732367/